← Back to Treatments
🏅 FDA Orphan Designation

Jascayd

NERANDOMILAST

Manufacturer: Boehringer Ingelheim Pharmaceuticals, Inc.

Indicated for:
Idiopathic pulmonary fibrosisOrphanHermansky-Pudlak syndrome due to BLOC-3 deficiency

FDA-Approved Indications (2)

treatment of idiopathic pulmonary fibrosis (IPF) in adult patients

The treatment of progressive pulmonary fibrosis in adult patients

Population: adults

Indications & Usage

1 INDICATIONS AND USAGE JASCAYD is a phosphodiesterase 4 (PDE4) inhibitor indicated for: The treatment of idiopathic pulmonary fibrosis in adult patients. ( 1.1 ) The treatment of progressive pulmonary fibrosis in adult patients. ( 1.2 ) 1.1 Idiopathic Pulmonary Fibrosis JASCAYD is indicated for the treatment of idiopathic pulmonary fibrosis (IPF) in adult patients. 1.2 Progressive Pulmonary Fibrosis JASCAYD is indicated for the treatment of progressive pulmonary fibrosis (PPF) in adult patients.

💙 Support Programs

View all →
JASCAYD
Indivior
Copay card ↗Apply ↗

Where shown, WAC (Wholesale Acquisition Cost) is an estimate only — your actual cost depends on your insurance plan. Always verify pricing with your pharmacy or insurer.

Medical disclaimer: This information is for educational purposes only. Always consult a qualified healthcare provider before making treatment decisions. Data sourced from FDA and current as of our last update.